|
|
Volumn 24, Issue 24, 2006, Pages 3821-3822
|
|
Some thoughts on the reporting of adverse events in phase II cancer clinical trials
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CANCER SURVIVAL;
CANCER THERAPY;
CLINICAL ASSESSMENT;
CLINICAL TRIAL;
DATA BASE;
DRUG SURVEILLANCE PROGRAM;
EDITORIAL;
HUMAN;
MEDICAL INFORMATION;
MEDICAL LITERATURE;
METASTASIS;
PEER REVIEW;
PRIORITY JOURNAL;
QUALITY CONTROL;
ECONOMICS;
FACTUAL DATABASE;
HEALTH CARE ORGANIZATION;
METHODOLOGY;
NEOPLASM;
NOTE;
PHASE 2 CLINICAL TRIAL;
POSTMARKETING SURVEILLANCE;
PUBLISHING;
STANDARD;
UNITED STATES;
ANTINEOPLASTIC AGENT;
ADVERSE DRUG REACTION REPORTING SYSTEMS;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS, PHASE II;
DATABASES, FACTUAL;
HUMANS;
NATIONAL INSTITUTES OF HEALTH (U.S.);
NEOPLASMS;
PRODUCT SURVEILLANCE, POSTMARKETING;
PUBLICATION BIAS;
RESEARCH DESIGN;
UNITED STATES;
|
|
EID: 33748466530
PISSN: 0732183X
EISSN: None
Source Type: Journal
DOI: 10.1200/JCO.2006.06.9856 Document Type: Editorial |
|
Times cited : (9)
|
|
References (7)
|
